CNBC 快讯 4月20日 13:02 礼来收购Kelonia：体内CAR-T并购浪潮的宏观定价逻辑 Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called… FG 100 读报告 →